DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Study Comparing Reduction and Viral Safety of IFN Alfa-2b XL + Ribavirin Versus PEG IFN Alfa-2b + Ribavirin in Patients With Chronic Hepatitis C Genotype 1

Information source: French National Agency for Research on AIDS and Viral Hepatitis
Information obtained from ClinicalTrials.gov on October 04, 2010
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Chronic Hepatitis C

Intervention: IFN alfa-2b XL 27 MUI + Ribavirin (Drug); IFN alfa-2b XL 36 MUI + Ribavirin (Drug); IFN peg alfa-2b 1.5 µg/kg + Ribavirin (Drug)

Phase: Phase 2

Status: Recruiting

Sponsored by: French National Agency for Research on AIDS and Viral Hepatitis

Official(s) and/or principal investigator(s):
Christian TREPO, MD, Principal Investigator, Affiliation: Hôpital Hotel Dieu, Service d'Hépatologie et de Gastro-Entérologie, 69288 Lyon CEDEX 02 - FRANCE

Overall contact:
Laurence ALLAIN, Phone: 33 1 53 94 60 47, Email: laurence.allain@anrs.fr


The purpose of this study is to confirm if IFN alfa-2b XL has a better antiviral activity and tolerability as compared with current marketed reference, while combined with ribavirin, in a 3-month therapy setting.

Clinical Details

Official title: ANRS HC 23 COAT-IFN

Study design: Allocation: Randomized, Control: Active Control, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Viral load decrease at Week 4 and Week 12 of treatment with IFN alfa-2b XL 27 MIU, IFN alfa-2b XL 36 MIU and the marketed reference product (PEG IFN alfa-2b 1.5μg/kg) in combination with ribavirin

Secondary outcome:

Percentage of patients with early virologic response (EVR) (reduction of at least 2 log viral load) at the end of week 12

Percentage of patients with complete early virologic response (EVR) (viral load <15 IU) at the end of the week 12

Detailed description: Interferon alfa-2b XL (IFN alfa-2b XL) is a novel sustained release interferon α-2b drug product that is being developed by FLAMEL TECHNOLOGIES using its Medusa® technology, aiming at reducing the toxicity and enhancing the biological response. In the present study, patients will be randomly assigned to either IFN alfa-2b XL 27 MUI, IFN alfa-2b XL 36 MUI, or IFN peg alfa-2b 1. 5 µg/kg, all administered once a week for 12 weeks by subcutaneous injections, in combination with weight dosed ribavirin daily administered orally in two divided doses. Doses will be adapted according to the dose modification guidelines for combination therapy labelled in the ribavirin prescribing information.


Minimum age: 18 Years. Maximum age: 65 Years. Gender(s): Both.


Inclusion Criteria:

- Patient having voluntarily signed the Informed Consent Form prior to any study

specific procedure being performed

- Male or female HCV genotype 1 infected patients (positive serum HCV RNA), aged

between 18 and 65 years inclusive, with a body mass within the range over or equal of 45Kg and below or equal to 100 Kg

- Patient being either naïve to therapy, either non-responder to previous standard

Peg-interferon α + ribavirin therapy,

- With no absolute contra-indication to interferon α or ribavirin

- Female patients must be non-lactating and of non-childbearing potential, or have a

negative pregnancy test results to enter the study

- No evidence of acute or advanced liver disease, uncontrolled diabetes,

cardiovascular, immunological, or thyroid disease, and no recently diagnosed malignancy

- Vital signs within normal ranges, or if outside the normal ranges, not deemed

clinically significant in the opinion of the Investigator. An ECG with no clinically significant abnormalities

Exclusion Criteria:

- History of solid organ transplantation

- Severe systemic infection, uncontrolled diabetes, cancers, associated liver disease

- General anesthesia or recent blood transfusion

Locations and Contacts

Laurence ALLAIN, Phone: 33 1 53 94 60 47, Email: laurence.allain@anrs.fr

Hôpital Hotel Dieu, Lyon 69288, France; Recruiting
Christian TREPO, MD, Phone: 33 4 72 41 30 88, Email: christian.trepo@chu-lyon.fr
Marianne MAYNARD, MD, Phone: 33 4 72 41 30 88, Email: marianne.maynard-muet@chu-lyon.fr
Additional Information

French National Agency for Research on AIDS and Viral Hepatitis website

Starting date: March 2010
Last updated: May 26, 2010

Page last updated: October 04, 2010

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015